Similarly, Raven has continued to make excellent progress with its
platform technology and clinical pipeline. Specifically, Raven's recent
progress includes the following:
-- On February 12th, Raven announced that four scientific abstracts
pertaining to its clinical and pre-clinical programs had been accepted
for presentation at the April meeting of the American Academy of Cancer
-- Following the completion of enrollment in the Phase 1/2a trial of its
lead clinical candidate RAV12 in mid-February, Raven announced on March
11th that the study results had been accepted for presentation at the
American Society of Clinical Oncology in May.
-- On March 13th, Raven announced that it had initiated a Phase 2 study of
RAV12 for the treatment of patients with metastatic pancreatic cancer.
These and other scientific presentations and announcements can be found on Raven's corporate website.
VaxGen believes that as the Raven research and development programs continue to progress and become more visible, the value of its discovery platform and potential oncology therapeutics will become increasingly evident. We further believe that the combination of Raven's science, discovery platforms and pipeline with VaxGen's late stage recombinant protein development, manufacturing expertise and financial resources will have a synergistic effect, enabling this promising pipeline to progress.
A few VaxGen stockholders continue to express opposition to the merger,
and it has come to our attention that there is commentary circulating which
is not factually correct. We are deeply concerned at this development and
believe that our stockholders deserve the opportunity to make an
|SOURCE VaxGen Inc.|
Copyright©2008 PR Newswire.
All rights reserved